02:04:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-23 Ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 Årsstämma 2024
2024-05-02 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-06-02 Årsstämma 2023
2023-06-02 Ordinarie utdelning VIMIAN 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-03-24 Extra Bolagsstämma 2023
2023-03-08 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-10-03 Extra Bolagsstämma 2022
2022-08-24 Kvartalsrapport 2022-Q2
2022-06-03 Ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-03-09 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2024-02-15 07:45:00

A strong platform for profitable growth

  • Revenue increased by 18 per cent to EUR 331.7m (281.3) with organic growth of 11 per cent
  • Adjusted EBITA reached EUR 87.3m (73.4) at a margin of 26.3 per cent (26.1)
  • Operating profit (EBIT) reached EUR 41.3m (39.4) including EUR 8m negative impact from litigation claim valuation adjustment
  • Profit for the period totalled EUR 10.5m (-7.2)
  • Earnings per share before and after dilution EUR 0.02 (-0.02)
  • Cash flow from operating activities of EUR -28.6m (25.3) impacted by the litigation payment in the second quarter, excluding this EUR 37.1m.

“In a year characterized by geopolitical uncertainty and a tough macroeconomy, Vimian stayed close to its customers and accelerated organic growth to 11 per cent, ahead of the animal health market. The adjusted EBITA margin improved to 26.3 per cent as Vimian progressed integration of acquired companies and efficiency measures deliver results”, says Patrik Eriksson, CEO of Vimian Group.

Revenue for the fourth quarter increased by 9 per cent to EUR 82.5m (75.5) with organic growth of 7 per cent. Adjusted EBITA reached EUR 22.6m (18.0) at a margin of 27.5 per cent (23.9).

“We deliver a solid fourth quarter with continued good growth and improved profitability. Looking ahead, Vimian’s overall strategy remains unchanged, and we will continue build strong global market positions in niches of the animal health market with unmet medical needs. Entering 2024, we continue to grow organically at high single digits, and see potential for some M&A discussions to pick up momentum during first half of this year. I see significant potential for value creation going forward through both organic and acquisition driven growth”, says Patrik Eriksson.

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=50046536

To attend the webcast:
Link: https://ir.financialhearings.com/vimian-group-q4-report-2023

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.